

ATTORNEY DOCKET NO MB 1124

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Zhu, et al.

Art Unit:

1647

Serial No.:

09/927,110

Examiner

Spector, L.

Filed:

August 10, 2001

Title:

METHOD FOR INHIBITING INFLAMMATION IN IMMUNE PRIVILEGED

SITES USING FAS LIGAND FRAGMENTS

Commissioner for Patents Washington, D.C. 20231

## TRANSMITTAL SHEET

Sir:

Transmitted herewith for the above-identified application, please find:

- (1) Response to Restriction Requirement mailed January 21, 2003 and Preliminary Amendment (8 pgs);
- (2) Petition for One Month Extension of Time (2 pgs);
- (3) Check # 532911 in the amount of \$55.00; and
- (4) Return Receipt Postcard.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on March 21, 2003, in an envelope addressed to:

Commissioner for Patents, Washington, D.C. 20231

Cara Grifone

In re Application of Zhu, et al..

Application No.: 09/927,110

Filed: August 10, 2001

Page 2

PATENT Attorney Docket No.: MBM1240

A check in the amount of \$55.00 is enclosed for the one month Extension of Time fee. The Commissioner is hereby authorized to charge any other fees that may be associated with this communication, or credit any overpayment to Deposit Account No. 50-1355.

Respectfully submitted,

Date: March 21, 2003

Lisa A. Haile, Ph.D. Registration No. 38,347 Telephone: (858) 677-1456 Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP 4365 Executive Drive, Suite 1100 San Diego, California 92121-2133 USPTO Customer Number 28213



ATTORNEY DOCKET NO.: MBI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Zhu, et al.

Art Unit:

1647

Serial No.:

09/927,110

Examiner

Spector, L.

Filed:

August 10, 2001

Title:

METHOD FOR INHIBITING INFLAMMATION IN IMMUNE PRIVILEGED

SITES USING FAS LIGAND FRAGMENTS

Commissioner for Patents Washington, D.C. 20231

## RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

Sir:

In response to the Requirement for Restriction mailed January 21, 2003, Applicants elect Group I, with traverse, consisting of claims 1-16, 20-22, and 42-44, drawn to a method of modulating inflammation in an immune privileged site using Fas ligand fragment (or a derivative thereof). In addition, Applicants request that the subject

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on March 21, 2003, in an envelope addressed to: Commissioner for Ratents, Washington, D.C. 20231

Mara &

ara Grifone

3/21/2003